Executive Summary
SGLT-2 inhibitors cut all-cause mortality 29% and heart failure hospitalizations 42% after TAVI in a pooled analysis of 35,075 patients published in JACC: Advances, putting a cheap pill on the post-TAVI checklist alongside the valve itself. Separately, a nine-RCT meta-analysis in JACC: Advances shows TAVR's early survival edge over SAVR in women disappears by year five, while intermediate/high-risk men actually do worse with TAVR long-term — which complicates the ESC 2025 push to TAVI as primary therapy at age 70. Bicuspid TAVR midterm data and a $1.5B Boston Scientific superalloy bet round out a day where the durability conversation got louder, not quieter.
- Pooled TAVI + SGLT-2i analysis (5 cohorts, 1 RCT, N=35,075) shows HR 0.71 for all-cause mortality but the evidence is mostly observational (JACC: Advances).
- TAVR's one-year mortality benefit in women vanishes at five years, and SAVR wins long-term in intermediate/high-risk men (JACC: Advances).
- Single-center BAV TAVR cohort (N=92, 2.9y follow-up) reports 26.1% all-cause mortality with no balloon-vs-self-expanding difference (JAHA).
- Dysphagia independently raised 90-day mortality after TAVR (HR 1.74) and SAVR (HR 1.34) in propensity-matched TriNetX cohorts (JAHA).
- Boston Scientific is staking $1.5B on a TAVR superalloy platform as it tries to crack the Edwards-Medtronic duopoly (Medical Design & Outsourcing).
What to watch: Edwards' Q2 earnings on July 23 will read against fresh CMS coverage proposals and a sex-stratified RCT meta-analysis that doesn't help the low-risk expansion narrative.
Aortic Valve (TAVR/TAVI)
The five-year sex-stratified meta-analysis is the more uncomfortable read of the day. Across nine RCTs and >9,500 patients, JACC: Advances reports a 33% relative reduction in the primary endpoint for women undergoing TAVR at one year — entirely lost by year five, with intermediate/high-risk men trending toward worse outcomes vs SAVR. This is exactly the durability tail that ACC/AHA 2020 flagged when it kept SAVR Class I for patients <65, and that ESC 2025 arguably underweighted when it dropped the TAVI-preferred threshold to age 70. The sex-disaggregated signal also undercuts the "TAVI for all" simplification.
The SGLT-2i meta-analysis (JACC: Advances, 35,075 patients, 5 of 6 studies observational, I²=75% for mortality) is hypothesis-generating, not practice-changing — but the effect sizes (HR 0.58 for HF hospitalization, HR 0.65 for MACE) are too large to ignore in a population where residual HF risk after a "successful" valve is the unsolved problem. Meanwhile, the CALLY index work (N=733, retrospective, single-center) found HR 3.31 for mortality in low-CALLY patients — another frailty/inflammation composite that won't replace STS-PROM but adds granularity. Dysphagia screening belongs in the pre-TAVR workup: HR 1.74 for 90-day mortality is not subtle.
The Cologne BAV TAVR series (N=92, single-center, 2.9y follow-up) reports 26.1% all-cause mortality and 14.1% stroke at midterm — the authors themselves call outcomes "suboptimal" and call for randomized trials vs surgery. ACC/AHA 2020 keeps BAV TAVI at Class IIb; ESC 2025 limits it to increased-surgical-risk patients with suitable anatomy. Today's data does nothing to relax those positions.
Mitral Valve (MitraClip, PASCAL, TMVR)
Geometry, not just severity, predicts who fails M-TEER in atrial functional MR. A JASE retrospective series of 130 AFMR patients (mean age 78, 93% AF, single-center) found the total leaflet area-to-annulus area ratio outperformed annulus area alone for predicting one-device success (AUC 0.79 vs 0.53). Lower TLA/MAA correlated with residual MR ≥2+, two-device strategy, and post-procedural mean gradient ≥5 mmHg. This is exactly the 3D-TEE preprocedural granularity ESC 2025 was implicitly calling for when it formalized atrial SMR as a distinct entity with its own management pathway — and which ACC/AHA 2020 did not.
Surgical counterpoint: ESC 2025 puts mitral valve surgery + surgical AF ablation + LAAO at Class IIa for atrial SMR with TEER reserved (Class IIb) for inoperable patients. The TLA/MAA finding helps stratify which AFMR anatomies are even repairable percutaneously — patients with small leaflet reserve relative to a dilated annulus probably belong on the surgical pathway, not the catheter lab table. A case report in J Cardiothoracic Surg documents late TMVI prosthesis dislodgement with severe hemolysis salvaged by transapical re-tensioning — a reminder that apical-fixation TMVI remains a high-stakes procedure even when "successful."
Tricuspid Valve (TriClip, TTVR)
Tricuspid annular diameter >39 mm predicts persistent moderate-or-greater TR a year after transcatheter ASD closure — and should push these patients toward surgical ASD closure with concomitant annuloplasty. The Polish prospective series (N=200, single-center) found 40% of patients had persistent ≥moderate TR at 12 months despite excellent reverse remodeling overall, with annular diameter the dominant independent predictor (OR 4.53; AUC 0.97). The 39 mm cutoff is clinically actionable.
This sits squarely within ESC 2025's expanded tricuspid framework — TV surgery for symptomatic primary TR is now Class I (upgraded from IIa in ACC/AHA 2020), and concomitant TV repair at the time of left-sided or shunt-correcting surgery has long been Class I when the annulus is dilated. The 39 mm threshold is tighter than the conventional 40 mm / 21 mm/m² used to trigger annuloplasty during left-sided surgery, and arguably should prompt structural heart teams to reconsider device-only ASD closure in this subset. No transcatheter tricuspid data today; the field still rests on TRILUMINATE, Tri.Fr, and TRISCEND II.
Surgical vs. Transcatheter Comparisons
Two findings reframe the surgical comparator today. First, the sex-stratified five-year RCT meta-analysis (JACC: Advances) — TAVR's early advantage in women disappears, and intermediate/high-risk men do directionally worse than with SAVR long-term. Second, the BAV TAVR midterm data (JAHA, N=92) with 26% mortality at 2.9 years explicitly call for randomized trials vs surgery. Both push the field back toward where ACC/AHA 2020 has held the line — SAVR retains a durability case in younger patients and in BAV anatomy. ESC 2025's age-70 TAVI threshold gets harder to defend when five-year sex-stratified outcomes don't favor TAVI uniformly.
Preprint Highlights
An agentic AI auto-discovery framework derived diastolic dysfunction phenotypes from surface 12-lead ECG with AUC 0.87 for severity classification, externally validated in 220,000 CODE-15% patients and 35,718 EchoNext patients (medRxiv). Subdistribution HRs for incident HF mortality ranged 5.5–9.5 and the model outperformed the published ECG2HF benchmark by ΔAUC 0.14–0.20. Preprint, not peer-reviewed, and the architecture optimization was LLM-driven — replication and prospective validation are non-negotiable before this enters valve-clinic triage. But the signal that diastolic phenotyping might run upstream of echo, in TAVR and MR populations where E/e' interpretation is messy, is real.
Device & Technology
Boston Scientific is staking $1.5B on a TAVR superalloy — frame metallurgy is one of the few remaining knobs to turn on next-generation transcatheter aortic platforms, where reducing crimped profile, leaflet stress, and crossing diameter all bear on durability and lifetime-management math. The bet only pencils if BSX believes there's room to displace Edwards SAPIEN and Medtronic Evolut on hard endpoints, not just delivery characteristics. FDA cleared an AI algorithm for flagging vascular disease — incremental, but part of the same pre-procedural workflow that will determine TF access feasibility for tomorrow's TAVR cases.
Regulatory & Policy
CMS has proposed updated TAVR Medicare coverage seen as favorable to Edwards. Separately, cardiology societies are opposing CMS's AI prior-authorization expansion, and hundreds of cardiologists were incorrectly added to a new mandatory payment model — administrative noise that nonetheless threatens to distort referral patterns. Joseph Woo took over as AATS president — surgical leadership for an organization whose voice in the SAVR-vs-TAVR conversation matters.
Industry & Market
Boston Scientific's $1.5B superalloy commitment to TAVR is the most consequential industry signal of the day — a clear statement that BSX intends to challenge Edwards/Medtronic in structural heart with materials innovation, not just delivery system refinement. Anteris (AVR.AX) jumped 10% on the day and is up 95% over six months as ComASUR generates investor interest. Edwards underperformed sector peers despite a 1.25% gain. CMS's proposed TAVR coverage update is the kind of reimbursement tailwind that supports the bull case for Edwards going into July earnings.
Financial Analysis
The sex-stratified RCT meta-analysis lands at an inconvenient moment for Edwards: the bull case rests on continued low-risk expansion, but five-year RCT data showing no benefit (and possible harm in intermediate/high-risk men) is the kind of finding that catches the next ACC/AHA writing committee's eye. The SGLT-2i meta-analysis is neutral-to-positive for Edwards in the sense that better post-TAVI outcomes support volume growth — but it also reframes residual HF risk as a pharmacological problem, not a valve problem. CMS coverage tailwind is real but incremental. Boston Scientific's $1.5B superalloy investment, in context, is a long-dated option on disrupting a duopoly — meaningful for capital allocation, immaterial for FY26 revenue.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Price: $86.95 (+1.25%); 6-mo +0.76%; 52-wk $72.30–$89.60
- Market cap: $50.1B; trailing P/E 47.0; forward P/E 25.8; beta 0.87
- Analyst target: $96.92 (buy, 26 analysts; range $84–$110)
- Next earnings: July 23, 2026; EPS est $0.74; Rev est $1.70B
- Read: CMS coverage proposal is a near-term tailwind. The JACC: Advances sex-stratified meta-analysis is the medium-term overhang — durability and patient selection conversations don't help low-risk expansion.
Medtronic (MDT)
- Price: $80.63 (+1.72%); 6-mo −15.82%; 52-wk $73.31–$106.33
- Market cap: $103.2B; trailing P/E 21.6; forward P/E 12.6; beta 0.60
- Analyst target: $98.00 (buy, 26 analysts)
- Next earnings: August 18, 2026; EPS est $1.39; Rev est $9.55B
- Read: Evolut continues to compete on hemodynamics and TAV-in-TAV-friendly design — the lifetime-management argument matters more as ESC 2025 pushes TAVI earlier.
Abbott (ABT)
- Price: $90.53 (+3.07%); 6-mo −26.64%
- Market cap: $157.7B; trailing P/E 25.4; forward P/E 14.9; beta 0.62
- Analyst target: $116.54 (buy, 24 analysts)
- Next earnings: July 16, 2026; EPS est $1.28; Rev est $12.53B
- Read: MitraClip benefits from ESC 2025's Class I upgrade for ventricular SMR. TriClip and Navitor remain real growth vectors in tricuspid and TAVR.
Boston Scientific (BSX)
- Price: $45.60 (+2.86%); 6-mo −52.56%
- Market cap: $67.8B; trailing P/E 19.1; forward P/E 12.3; beta 0.56
- Analyst target: $77.04 (buy, 28 analysts)
- Next earnings: July 29, 2026; EPS est $0.83; Rev est $5.37B
- Read: The $1.5B TAVR superalloy bet is a structural pivot, not a quarterly catalyst. ACURATE Prime and the broader structural heart franchise need a durable platform to close the gap with EW and MDT.
Anteris Technologies (AVR.AX)
- Price: $15.00 (+10.05%); 6-mo +94.81%; 52-wk $4.68–$15.00
- Market cap: $1.5B; forward P/E −6.88; beta 0.73
- Analyst target: $13.00 (1 analyst)
- Read: Hit a new 52-week high. ComASUR single-piece valve narrative remains the differentiator; clinical data will determine whether the rally has legs.
Market outlook: Structural heart names are pricing in continued procedural volume growth but reacting more sensitively to durability and patient-selection signals than to top-line beats. Today's sex-stratified five-year meta-analysis is the kind of finding that doesn't move the stock tomorrow but anchors the next guideline-update narrative.
Clinical Trial Updates
Mitral Repair
- NCT07662655 — Percutaneous Pulmonary Artery Denervation (PADN) for Pulmonary Hypertension After M-TEER. Status: RECRUITING; Phase: Early Phase 1; Enrollment: 60; Sponsor: Xiamen Cardiovascular Hospital. Tests whether catheter denervation of the pulmonary artery can address residual pulmonary hypertension after successful TEER — a known driver of persistent symptoms and HF readmission in the COAPT-eligible population. Small, early-phase, but addresses a real unsolved problem in the ESC 2025 Class I indication.
Tomorrow: watch for whether the BAV-TAVR randomized trial drumbeat translates into formal protocol announcements, and how Edwards positions the JACC: Advances sex-stratified data going into July 23 earnings.
— E. Nolan Beckett, MD